Vimian Group AB (VIMIAN) - Total Liabilities
Based on the latest financial reports, Vimian Group AB (VIMIAN) has total liabilities worth Skr401.00 Million SEK (≈ $43.15 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Vimian Group AB (VIMIAN) cash flow conversion to assess how effectively this company generates cash.
Vimian Group AB - Total Liabilities Trend (2017–2025)
This chart illustrates how Vimian Group AB's total liabilities have evolved over time, based on quarterly financial data. See VIMIAN book value for net asset value and shareholders' equity analysis.
Vimian Group AB Competitors by Total Liabilities
The table below lists competitors of Vimian Group AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Magnite Inc
NASDAQ:MGNI
|
USA | $2.24 Billion |
|
BASF India Limited
NSE:BASF
|
India | Rs38.85 Billion |
|
Nurix Therapeutics Inc
NASDAQ:NRIX
|
USA | $150.22 Million |
|
F&F Co Ltd
KO:383220
|
Korea | ₩750.16 Billion |
|
CITIC Guoan Information Industry Co Ltd
SHE:000839
|
China | CN¥5.24 Billion |
|
Monarch Casino & Resort Inc
NASDAQ:MCRI
|
USA | $175.18 Million |
|
Chongqing Iron & Steel Co Ltd Class A
SHG:601005
|
China | CN¥18.67 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down Vimian Group AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Vimian Group AB market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.95 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.57 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.36 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vimian Group AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vimian Group AB (2017–2025)
The table below shows the annual total liabilities of Vimian Group AB from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr401.00 Million ≈ $43.15 Million |
-0.57% |
| 2024-12-31 | Skr403.30 Million ≈ $43.40 Million |
-9.77% |
| 2023-12-31 | Skr446.97 Million ≈ $48.10 Million |
+1.11% |
| 2022-12-31 | Skr442.06 Million ≈ $47.57 Million |
+56.72% |
| 2021-12-31 | Skr282.08 Million ≈ $30.36 Million |
+54.95% |
| 2020-12-31 | Skr182.05 Million ≈ $19.59 Million |
+286.72% |
| 2019-12-31 | Skr47.08 Million ≈ $5.07 Million |
+244.90% |
| 2018-12-31 | Skr13.65 Million ≈ $1.47 Million |
-- |
| 2017-12-31 | Skr0.00 ≈ $0.00 |
-- |
About Vimian Group AB
Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic… Read more